Follow the people · Insider
Sarah Gheuens
Sarah Gheuens files insider transactions with the SEC as a chief medical officer of Agios Pharmaceuticals (AGIO). We hold 5 disclosed purchases and sales filed since 7 December 2021, 2 of them in the last 90 days.
- Files forAGIO
- Disclosed buys and sells5 in all, 2 in the last 90 days
- Last disclosure6 August 2026
Positions held
2 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 2 December 2021 — 4 August 2026Chief Medical Officer · Agios Pharmaceuticals (AGIO)118 Form 4 lines · source: SEC Form 4
- Filed 21 September 2023 — 1 July 2026Director · Viridian Therapeutics, Inc.\DE (VRDN)4 Form 4 lines · source: SEC Form 4
Everything they disclosed
120 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 30,000 shares of Agios PharmaceuticalsSEC Form 46 August 2026Common stock · traded 4 August 2026 · filed 6 August 2026
- was granted 32,341 shares of Viridian Therapeutics, Inc.\DE (a derivative holding)SEC Form 42 July 2026Stock Option (Right to Buy) · traded 1 July 2026 · filed 2 July 2026
- exercised options over 8,375 shares of Agios PharmaceuticalsSEC Form 42 July 2026Common stock · traded 1 July 2026 · filed 2 July 2026
- ▼ sold on the open market 4,007 shares of Agios PharmaceuticalsSEC Form 42 July 2026Common stock · traded 1 July 2026 · filed 2 July 2026
- exercised options over 8,375 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 42 July 2026Restricted stock units · traded 1 July 2026 · filed 2 July 2026
- exercised options over 3,000 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 423 June 2026Performance share units · traded 18 June 2026 · filed 23 June 2026
- was granted 3,000 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 423 June 2026Restricted stock units · traded 18 June 2026 · filed 23 June 2026
- exercised options over 8,500 shares of Agios PharmaceuticalsSEC Form 46 April 2026Common stock · traded 2 April 2026 · filed 6 April 2026
- ▼ sold on the open market 2,940 shares of Agios PharmaceuticalsSEC Form 46 April 2026Common stock · traded 2 April 2026 · filed 6 April 2026
- exercised options over 8,500 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 46 April 2026Performance share units · traded 2 April 2026 · filed 6 April 2026
- exercised options over 4,000 shares of Agios PharmaceuticalsSEC Form 43 March 2026Common stock · traded 2 March 2026 · filed 3 March 2026
- exercised options over 4,000 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 43 March 2026Restricted stock units · traded 2 March 2026 · filed 3 March 2026
- exercised options over 5,666 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 43 March 2026Restricted stock units · traded 2 March 2026 · filed 3 March 2026
- exercised options over 4,000 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 43 March 2026Restricted stock units · traded 2 March 2026 · filed 3 March 2026
- ▼ sold on the open market 1,187 shares of Agios PharmaceuticalsSEC Form 43 March 2026Common stock · traded 2 March 2026 · filed 3 March 2026
- exercised options over 5,666 shares of Agios PharmaceuticalsSEC Form 43 March 2026Common stock · traded 2 March 2026 · filed 3 March 2026
- was granted 14,000 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 43 March 2026Restricted stock units · traded 1 March 2026 · filed 3 March 2026
- was granted 22,000 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 43 March 2026Restricted stock units · traded 1 March 2026 · filed 3 March 2026
- was granted 52,000 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 43 March 2026Stock options (right to buy) · traded 1 March 2026 · filed 3 March 2026
- exercised options over 4,000 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 43 March 2026Restricted stock units · traded 2 March 2026 · filed 3 March 2026
- exercised options over 5,666 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 43 March 2026Restricted stock units · traded 2 March 2026 · filed 3 March 2026
- exercised options over 4,000 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 43 March 2026Restricted stock units · traded 2 March 2026 · filed 3 March 2026
- ▼ sold on the open market 1,681 shares of Agios PharmaceuticalsSEC Form 43 March 2026Common stock · traded 2 March 2026 · filed 3 March 2026
- exercised options over 4,000 shares of Agios PharmaceuticalsSEC Form 43 March 2026Common stock · traded 2 March 2026 · filed 3 March 2026
- ▼ sold on the open market 1,187 shares of Agios PharmaceuticalsSEC Form 43 March 2026Common stock · traded 2 March 2026 · filed 3 March 2026
- was granted 14,000 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 43 March 2026Restricted stock units · traded 1 March 2026 · filed 3 March 2026
- was granted 22,000 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 43 March 2026Restricted stock units · traded 1 March 2026 · filed 3 March 2026
- exercised options over 4,000 shares of Agios PharmaceuticalsSEC Form 43 March 2026Common stock · traded 2 March 2026 · filed 3 March 2026
- ▼ sold on the open market 1,187 shares of Agios PharmaceuticalsSEC Form 43 March 2026Common stock · traded 2 March 2026 · filed 3 March 2026
- exercised options over 5,666 shares of Agios PharmaceuticalsSEC Form 43 March 2026Common stock · traded 2 March 2026 · filed 3 March 2026
- ▼ sold on the open market 1,681 shares of Agios PharmaceuticalsSEC Form 43 March 2026Common stock · traded 2 March 2026 · filed 3 March 2026
- exercised options over 4,000 shares of Agios PharmaceuticalsSEC Form 43 March 2026Common stock · traded 2 March 2026 · filed 3 March 2026
- ▼ sold on the open market 1,187 shares of Agios PharmaceuticalsSEC Form 43 March 2026Common stock · traded 2 March 2026 · filed 3 March 2026
- was granted 52,000 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 43 March 2026Stock options (right to buy) · traded 1 March 2026 · filed 3 March 2026
- exercised options over 6,000 shares of Agios PharmaceuticalsSEC Form 42 January 2026Common stock · traded 30 December 2025 · filed 2 January 2026
- ▼ sold on the open market 2,932 shares of Agios PharmaceuticalsSEC Form 42 January 2026Common stock · traded 30 December 2025 · filed 2 January 2026
- exercised options over 6,000 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 42 January 2026Performance share units · traded 30 December 2025 · filed 2 January 2026
- exercised options over 6,000 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 42 January 2026Performance share units · traded 30 December 2025 · filed 2 January 2026
- exercised options over 6,000 shares of Agios PharmaceuticalsSEC Form 42 January 2026Common stock · traded 30 December 2025 · filed 2 January 2026
- ▼ sold on the open market 2,932 shares of Agios PharmaceuticalsSEC Form 42 January 2026Common stock · traded 30 December 2025 · filed 2 January 2026
- exercised options over 2,454 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 413 November 2025Stock options (right to buy) · traded 11 November 2025 · filed 13 November 2025
- exercised options over 2,454 shares of Agios PharmaceuticalsSEC Form 413 November 2025Common stock · traded 11 November 2025 · filed 13 November 2025
- ▼ sold on the open market 2,454 shares of Agios PharmaceuticalsSEC Form 413 November 2025Common stock · traded 11 November 2025 · filed 13 November 2025
- exercised options over 200 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 43 November 2025Stock options (right to buy) · traded 30 October 2025 · filed 3 November 2025
- exercised options over 200 shares of Agios PharmaceuticalsSEC Form 43 November 2025Common stock · traded 30 October 2025 · filed 3 November 2025
- ▼ sold on the open market 200 shares of Agios PharmaceuticalsSEC Form 43 November 2025Common stock · traded 30 October 2025 · filed 3 November 2025
- exercised options over 3,302 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 429 October 2025Stock options (right to buy) · traded 27 October 2025 · filed 29 October 2025
- exercised options over 3,302 shares of Agios PharmaceuticalsSEC Form 429 October 2025Common stock · traded 27 October 2025 · filed 29 October 2025
- ▼ sold on the open market 3,302 shares of Agios PharmaceuticalsSEC Form 429 October 2025Common stock · traded 27 October 2025 · filed 29 October 2025
- exercised options over 11,914 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 411 July 2025Stock options (right to buy) · traded 9 July 2025 · filed 11 July 2025
- exercised options over 11,914 shares of Agios PharmaceuticalsSEC Form 411 July 2025Common stock · traded 9 July 2025 · filed 11 July 2025
- ▼ sold on the open market 11,067 shares of Agios PharmaceuticalsSEC Form 411 July 2025Common stock · traded 9 July 2025 · filed 11 July 2025
- ▼ sold on the open market 847 shares of Agios PharmaceuticalsSEC Form 411 July 2025Common stock · traded 9 July 2025 · filed 11 July 2025
- exercised options over 8,374 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 43 July 2025Restricted stock units · traded 1 July 2025 · filed 3 July 2025
- exercised options over 8,374 shares of Agios PharmaceuticalsSEC Form 43 July 2025Common stock · traded 1 July 2025 · filed 3 July 2025
- ▼ sold on the open market 4,091 shares of Agios PharmaceuticalsSEC Form 43 July 2025Common stock · traded 1 July 2025 · filed 3 July 2025
- was granted 21,000 shares of Viridian Therapeutics, Inc.\DE (a derivative holding)SEC Form 42 July 2025Stock Option (Right to Buy) · traded 1 July 2025 · filed 2 July 2025
- exercised options over 6,000 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 426 June 2025Performance share units · traded 24 June 2025 · filed 26 June 2025
- exercised options over 6,000 shares of Agios PharmaceuticalsSEC Form 426 June 2025Common stock · traded 24 June 2025 · filed 26 June 2025
- ▼ sold on the open market 2,909 shares of Agios PharmaceuticalsSEC Form 426 June 2025Common stock · traded 24 June 2025 · filed 26 June 2025
- was granted 12,000 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 44 March 2025Restricted stock units · traded 1 March 2025 · filed 4 March 2025
- was granted 43,500 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 44 March 2025Stock options (right to buy) · traded 1 March 2025 · filed 4 March 2025
- exercised options over 3,833 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 44 March 2025Restricted stock units · traded 1 March 2025 · filed 4 March 2025
- exercised options over 4,000 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 44 March 2025Restricted stock units · traded 1 March 2025 · filed 4 March 2025
- exercised options over 5,667 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 44 March 2025Restricted stock units · traded 1 March 2025 · filed 4 March 2025
- exercised options over 3,833 shares of Agios PharmaceuticalsSEC Form 44 March 2025Common stock · traded 1 March 2025 · filed 4 March 2025
- ▼ sold on the open market 1,137 shares of Agios PharmaceuticalsSEC Form 44 March 2025Common stock · traded 3 March 2025 · filed 4 March 2025
- exercised options over 4,000 shares of Agios PharmaceuticalsSEC Form 44 March 2025Common stock · traded 1 March 2025 · filed 4 March 2025
- ▼ sold on the open market 1,187 shares of Agios PharmaceuticalsSEC Form 44 March 2025Common stock · traded 3 March 2025 · filed 4 March 2025
- exercised options over 5,667 shares of Agios PharmaceuticalsSEC Form 44 March 2025Common stock · traded 1 March 2025 · filed 4 March 2025
- ▼ sold on the open market 1,681 shares of Agios PharmaceuticalsSEC Form 44 March 2025Common stock · traded 3 March 2025 · filed 4 March 2025
- exercised options over 8,375 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 43 July 2024Restricted stock units · traded 1 July 2024 · filed 3 July 2024
- exercised options over 8,375 shares of Agios PharmaceuticalsSEC Form 43 July 2024Common stock · traded 1 July 2024 · filed 3 July 2024
- ▼ sold on the open market 3,705 shares of Agios PharmaceuticalsSEC Form 43 July 2024Common stock · traded 1 July 2024 · filed 3 July 2024
- was granted 21,000 shares of Viridian Therapeutics, Inc.\DE (a derivative holding)SEC Form 428 June 2024Stock Option (Right to Buy) · traded 26 June 2024 · filed 28 June 2024
- was granted 17,000 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 45 March 2024Restricted stock units · traded 1 March 2024 · filed 5 March 2024
- was granted 60,000 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 45 March 2024Stock options (right to buy) · traded 1 March 2024 · filed 5 March 2024
- exercised options over 3,834 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 45 March 2024Restricted stock units · traded 1 March 2024 · filed 5 March 2024
- exercised options over 4,000 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 45 March 2024Restricted stock units · traded 1 March 2024 · filed 5 March 2024
- exercised options over 3,834 shares of Agios PharmaceuticalsSEC Form 45 March 2024Common stock · traded 1 March 2024 · filed 5 March 2024
- ▼ sold on the open market 1,293 shares of Agios PharmaceuticalsSEC Form 45 March 2024Common stock · traded 5 March 2024 · filed 5 March 2024
- exercised options over 4,000 shares of Agios PharmaceuticalsSEC Form 45 March 2024Common stock · traded 1 March 2024 · filed 5 March 2024
- ▼ sold on the open market 1,349 shares of Agios PharmaceuticalsSEC Form 45 March 2024Common stock · traded 5 March 2024 · filed 5 March 2024
- exercised options over 2,162 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 414 February 2024Restricted stock units · traded 12 February 2024 · filed 14 February 2024
- exercised options over 2,162 shares of Agios PharmaceuticalsSEC Form 414 February 2024Common stock · traded 12 February 2024 · filed 14 February 2024
- ▼ sold on the open market 642 shares of Agios PharmaceuticalsSEC Form 414 February 2024Common stock · traded 14 February 2024 · filed 14 February 2024
- exercised options over 5,750 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 424 January 2024Performance share units · traded 20 January 2024 · filed 24 January 2024
- exercised options over 5,750 shares of Agios PharmaceuticalsSEC Form 424 January 2024Common stock · traded 20 January 2024 · filed 24 January 2024
- ▼ sold on the open market 1,708 shares of Agios PharmaceuticalsSEC Form 424 January 2024Common stock · traded 24 January 2024 · filed 24 January 2024
- exercised options over 5,000 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 49 January 2024Performance share units · traded 5 January 2024 · filed 9 January 2024
- exercised options over 5,000 shares of Agios PharmaceuticalsSEC Form 49 January 2024Common stock · traded 5 January 2024 · filed 9 January 2024
- ▼ sold on the open market 1,789 shares of Agios PharmaceuticalsSEC Form 49 January 2024Common stock · traded 9 January 2024 · filed 9 January 2024
- was granted 40,000 shares of Viridian Therapeutics, Inc.\DE (a derivative holding)SEC Form 425 September 2023Stock Option (Right to Buy) · traded 21 September 2023 · filed 25 September 2023
- was granted 25,124 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 46 July 2023Restricted stock units · traded 1 July 2023 · filed 6 July 2023
- exercised options over 5,750 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 430 June 2023Performance share units · traded 28 June 2023 · filed 30 June 2023
- exercised options over 5,750 shares of Agios PharmaceuticalsSEC Form 430 June 2023Common stock · traded 28 June 2023 · filed 30 June 2023
- ▼ sold on the open market 1,707 shares of Agios PharmaceuticalsSEC Form 430 June 2023Common stock · traded 30 June 2023 · filed 30 June 2023
- was granted 12,000 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 43 March 2023Restricted stock units · traded 1 March 2023 · filed 3 March 2023
- was granted 44,000 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 43 March 2023Stock options (right to buy) · traded 1 March 2023 · filed 3 March 2023
- exercised options over 3,833 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 43 March 2023Restricted stock units · traded 1 March 2023 · filed 3 March 2023
- exercised options over 3,833 shares of Agios PharmaceuticalsSEC Form 43 March 2023Common stock · traded 1 March 2023 · filed 3 March 2023
- had shares withheld for tax on 1,134 shares of Agios PharmaceuticalsSEC Form 43 March 2023Common stock · traded 3 March 2023 · filed 3 March 2023
- exercised options over 2,162 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 414 February 2023Restricted stock units · traded 10 February 2023 · filed 14 February 2023
- exercised options over 2,162 shares of Agios PharmaceuticalsSEC Form 414 February 2023Common stock · traded 10 February 2023 · filed 14 February 2023
- had shares withheld for tax on 758 shares of Agios PharmaceuticalsSEC Form 414 February 2023Common stock · traded 14 February 2023 · filed 14 February 2023
- exercised options over 9,375 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 428 December 2022Restricted stock units · traded 23 December 2022 · filed 28 December 2022
- exercised options over 9,375 shares of Agios PharmaceuticalsSEC Form 428 December 2022Common stock · traded 23 December 2022 · filed 28 December 2022
- had shares withheld for tax on 2,783 shares of Agios PharmaceuticalsSEC Form 428 December 2022Common stock · traded 28 December 2022 · filed 28 December 2022
- exercised options over 833 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 46 December 2022Restricted stock units · traded 2 December 2022 · filed 6 December 2022
- exercised options over 833 shares of Agios PharmaceuticalsSEC Form 46 December 2022Common stock · traded 2 December 2022 · filed 6 December 2022
- had shares withheld for tax on 248 shares of Agios PharmaceuticalsSEC Form 46 December 2022Common stock · traded 6 December 2022 · filed 6 December 2022
- was granted 11,500 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 43 March 2022Restricted stock units · traded 1 March 2022 · filed 3 March 2022
- was granted 41,000 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 43 March 2022Stock options (right to buy) · traded 1 March 2022 · filed 3 March 2022
- exercised options over 3,271 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 423 February 2022Performance share units · traded 18 February 2022 · filed 23 February 2022
- exercised options over 3,271 shares of Agios PharmaceuticalsSEC Form 423 February 2022Common stock · traded 18 February 2022 · filed 23 February 2022
- had shares withheld for tax on 955 shares of Agios PharmaceuticalsSEC Form 423 February 2022Common stock · traded 22 February 2022 · filed 23 February 2022
- exercised options over 2,162 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 414 February 2022Restricted stock units · traded 10 February 2022 · filed 14 February 2022
- exercised options over 2,162 shares of Agios PharmaceuticalsSEC Form 414 February 2022Common stock · traded 10 February 2022 · filed 14 February 2022
- had shares withheld for tax on 758 shares of Agios PharmaceuticalsSEC Form 414 February 2022Common stock · traded 10 February 2022 · filed 14 February 2022
- exercised options over 834 shares of Agios Pharmaceuticals (a derivative holding)SEC Form 47 December 2021Restricted stock units · traded 2 December 2021 · filed 7 December 2021
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.